These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23378663)

  • 21. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fabry disease. A case report.
    Kotnik J; Kotnik F; Desnick RJ
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):15-9. PubMed ID: 15818441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter regarding Brouns et Al, Baptista et Al, and Wozniak et Al.
    Lidove O; Joly D; Touzé E
    Stroke; 2011 Jan; 42(1):e4-5; author reply e6-7. PubMed ID: 21148443
    [No Abstract]   [Full Text] [Related]  

  • 26. Fabry disease--a primer for cardiologists.
    Mursă A; Ginghină C; Jurcut R
    Rom J Intern Med; 2014; 52(4):216-22. PubMed ID: 25726623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression of Fabry cardiomyopathy despite enzyme replacement therapy.
    Pieroni M; Camporeale A; Della Bona R; Sabini A; Cosmi D; Magnolfi A; Bolognese L
    Circulation; 2013 Oct; 128(15):1687-8. PubMed ID: 24100483
    [No Abstract]   [Full Text] [Related]  

  • 28. Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients.
    De Schoenmakere G; Poppe B; Wuyts B; Claes K; Cassiman D; Maes B; Verbeelen D; Vanholder R; Kuypers DR; Lameire N; De Paepe A; Terryn W
    Nephrol Dial Transplant; 2008 Dec; 23(12):4044-8. PubMed ID: 18596132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Renal insufficiency manifesting a heterozygote form of Fabry's disease].
    Hainaut P; Mugabo P; Schapira M; Coche E
    Acta Clin Belg; 1988; 43(5):374-7. PubMed ID: 3144819
    [No Abstract]   [Full Text] [Related]  

  • 30. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrafamilial phenotypic variability in four families with Anderson-Fabry disease.
    Rigoldi M; Concolino D; Morrone A; Pieruzzi F; Ravaglia R; Furlan F; Santus F; Strisciuglio P; Torti G; Parini R
    Clin Genet; 2014 Sep; 86(3):258-63. PubMed ID: 23980562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An unusual case of chronic renal failure.
    Manoj AL; Dhaygude A
    Postgrad Med J; 2002 Feb; 78(916):103-4, 110-1. PubMed ID: 11807199
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapy of Fabry disease.
    Kleinert J; Hauser AC; Lorenz M; Födinger M; Sunder-Plassmann G
    Kidney Int; 2004 Sep; 66(3):1288; author reply 1288-9. PubMed ID: 15327431
    [No Abstract]   [Full Text] [Related]  

  • 34. Thyroid function in Fabry disease before and after enzyme replacement therapy.
    Faggiano A; Severino R; Ramundo V; Russo R; Vuolo L; Del Prete M; Marciello F; Lombardi G; Cianciaruso B; Colao A; Pisani A
    Minerva Endocrinol; 2011 Mar; 36(1):1-5. PubMed ID: 21460782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients.
    Nishino T; Obata Y; Furusu A; Hirose M; Shinzato K; Hattori K; Nakamura K; Matsumoto T; Endo F; Kohno S
    Ren Fail; 2012; 34(5):566-70. PubMed ID: 22563919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
    Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
    Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.